Model Medicines Selected to Participate at the 2022 BMO Healthcare Conference, Following Announcement of their Oncology Program and Subsequent Drug Compounds for Two Oncology Targets
Dr. Daniel Haders, founder and CEO of Model Medicines will be presenting at this year’s BMO Healthcare Conference in New York City, speaking to the recent announcement by the company around their Oncology Program
Following the launch of its oncology programs, Model Medicines announced multiple AI-discovered compounds demonstrating drug-like activity for two high value, difficult to drug, oncogenic and epigenetic targets.
LA JOLLA, CA., October 4, 2022 -- Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company will participate in the BMO Healthcare Conference in New York, October 13th, 2022. This announcement follows recent positive data the company recently released surrounding it’s newly created Oncology program with multiple AI-discovered compounds demonstrating drug-like activity for two high value, difficult to drug, oncogenic and epigenetic targets. This announcement follows the company’s Q2 2022 announcement that its AI-discovered lead compound, MDL-001, developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai, demonstrated preclinical proof-of-concept and best-in-class characteristics as a potential broad spectrum infectious disease therapeutic.
Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s BMO Healthcare Conference, presenting data surrounding their four drug programs of infectious disease, oncology, gastrointestinal motility, and inflamation and rare disease.
ABOUT BMO
BMO Capital Markets is a leading, full-service financial services provider. We offer corporate and investment banking, treasury management, as well as research and advisory services to clients around the world. As a member of BMO Financial Group (NYSE, TSX: BMO), we’re part of one of the largest diversified financial services providers in North America with US$812 billion total assets and approximately 45,000 employees as of April 30, 2022. BMO Financial Group is the 8th largest bank in North America as measured by assets (Bloomberg, as of April 30, 2022). Learn more in our Annual Report.
We have over 2,600 professionals in 32 locations around the world, including 18 offices in North America. Learn more at https://capitalmarkets.bmo.com
ABOUT MODEL MEDICINES
Model Medicines is a pharmatech company working to transform the drug discovery and development industry by accelerating the creation of life-changing drugs using artificial intelligence and machine learning. Model Medicines was started in 2019 to deliver on the promise of AI-Drug discovery. With more than 90+ assets for 10+ targets, we are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA. www.modelmedicines.com
